China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma Nippon Kayaku Co., Ltd. This strategic partnership grants Nippon Kayaku marketing and distribution rights for AnHeart’s leading pipeline candidate, taletrectinib, a next-generation ROS1 inhibitor.
Taletrectinib: A Promising Treatment for ROS1-Positive NSCLC
Taletrectinib is an oral, potent, brain-penetrant, selective inhibitor being evaluated for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). It is positioned as a potential best-in-class therapy, offering hope for patients with this specific type of lung cancer.
Deal Terms and Financial Commitments
Under the terms of the agreement, Nippon Kayaku will make an upfront payment of USD 40 million to AnHeart Therapeutics. Additionally, there are undisclosed milestone commitments and royalties on future net sales, reflecting the potential of taletrectinib in the market.
Clinical Progress and Efficacy Data
AnHeart has advanced taletrecitinib to Phase II clinical trials, with earlier data this year indicating its potential as a best-in-class drug for ROS1-positive NSCLC. Interim results demonstrated that taletrectinib shrank tumors in over 90% of patients who had not previously received a ROS1 tyrosine kinase inhibitor (TKI), and in more than 50% of patients who had previously received a ROS1 TKI. The drug was also well-tolerated, with a low incidence of neurological adverse events, highlighting its safety profile.
Conclusion
The exclusive license deal between AnHeart Therapeutics and Nippon Kayaku marks a significant step in the global development of taletrectinib. This collaboration aims to expedite the drug’s journey towards regulatory approval and market availability, ultimately benefiting patients with ROS1-positive NSCLC and potentially other indications.-Fineline Info & Tech
